{
    "id": 14359,
    "fullName": "PIM1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "PIM1 over exp indicates an over expression of the Pim1 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5292,
        "geneSymbol": "PIM1",
        "terms": [
            "PIM1",
            "PIM"
        ]
    },
    "variant": "over exp",
    "createDate": "11/23/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4891,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, urinary bladder cancer cells over expressing PIM1 were sensitive to TP-3654 both in culture and in human cell line xenograft models, resulting in decreased tumor growth (PMID: 24953177).",
            "molecularProfile": {
                "id": 14615,
                "profileName": "PIM1 over exp"
            },
            "therapy": {
                "id": 3672,
                "therapyName": "TP-3654",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4769,
                    "pubMedId": 24953177,
                    "title": "A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24953177"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4886,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells over expressing PIM1 were sensitive to TP-3654 both in culture and in human cell line xenograft models, resulting in decreased tumor growth (PMID: 24953177).",
            "molecularProfile": {
                "id": 14615,
                "profileName": "PIM1 over exp"
            },
            "therapy": {
                "id": 3672,
                "therapyName": "TP-3654",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4769,
                    "pubMedId": 24953177,
                    "title": "A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24953177"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4894,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cells with PIM1 overexpression demonstrated sensitivity to K00135 in culture, resulting in reduced cell survival (PMID: 21993851).",
            "molecularProfile": {
                "id": 14615,
                "profileName": "PIM1 over exp"
            },
            "therapy": {
                "id": 3674,
                "therapyName": "K00135",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4427,
                    "pubMedId": 21993851,
                    "title": "Clinical and therapeutic relevance of PIM1 kinase in gastric cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21993851"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3676,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 treatment decreased proliferation, increased apoptosis, and inhibited growth of tumor grafts derived from mouse primary prostate epithelial cells over-expressing Myc and Pim1 (PMID: 25505253).",
            "molecularProfile": {
                "id": 14616,
                "profileName": "MYC over exp PIM1 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3983,
                    "pubMedId": 25505253,
                    "title": "PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25505253"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4587,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 treatment inhibited proliferation of JAK2 inhibitor-resistant myeloproliferative cancer cell lines harboring JAK2 V617F and elevated protein level of PIM1, PIM2 AND PIM3 in culture (PMID: 26472029).",
            "molecularProfile": {
                "id": 18597,
                "profileName": "JAK2 V617F PIM1 over exp PIM2 over exp PIM3 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 4960,
                "name": "bone marrow cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4621,
                    "pubMedId": 26472029,
                    "title": "The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26472029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4588,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of Pim1 in JAK2 V617F-transformed B cell lines induced resistance to growth inhibition by Jakafi (ruxolitinib) (PMID: 26472029).",
            "molecularProfile": {
                "id": 18598,
                "profileName": "JAK2 V617F PIM1 over exp"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4621,
                    "pubMedId": 26472029,
                    "title": "The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26472029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4589,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of Pim1 in MPL W515L-transformed myeloid cell lines induced resistance to growth inhibition by Jakafi (ruxolitinib) (PMID: 26472029).",
            "molecularProfile": {
                "id": 18599,
                "profileName": "MPL W515L PIM1 over exp"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4621,
                    "pubMedId": 26472029,
                    "title": "The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26472029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4893,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, leukemia cells harboring a FLT3 ITD and PIM1 over expression were sensitive to SMI-4a, demonstrating inhibition of cell growth (PMID: 19965690).",
            "molecularProfile": {
                "id": 19449,
                "profileName": "FLT3 exon 14 ins PIM1 over exp"
            },
            "therapy": {
                "id": 3673,
                "therapyName": "SMI-4a",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4771,
                    "pubMedId": 19965690,
                    "title": "A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19965690"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7249,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 decreased viability of colon cancer cells with hypoxia-induced increased expression of Pim1 and Pim2 in culture (PMID: 27196781).",
            "molecularProfile": {
                "id": 24804,
                "profileName": "PIM1 over exp PIM2 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6257,
                    "pubMedId": 27196781,
                    "title": "PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196781"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7245,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a prostate cancer cell line with hypoxia-induced increased expression of Pim1 and Pim2 demonstrated sensitivity to AZD1208 in culture and in xenograft models (PMID: 27196781).",
            "molecularProfile": {
                "id": 24804,
                "profileName": "PIM1 over exp PIM2 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6257,
                    "pubMedId": 27196781,
                    "title": "PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196781"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7247,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 decreased viability of breast cancer cells with hypoxia-induced increased expression of Pim1 and Pim2 in culture (PMID: 27196781).",
            "molecularProfile": {
                "id": 24804,
                "profileName": "PIM1 over exp PIM2 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6257,
                    "pubMedId": 27196781,
                    "title": "PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196781"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8913,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to MK2206 in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8916,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Afinitor (everolimus) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8917,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Torkinib (PP242) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 2240,
                "therapyName": "Torkinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8909,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Taselisib (GDC-0032) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8915,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Rapamune (sirolimus) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8918,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to WYE-354 in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 2243,
                "therapyName": "WYE-354",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8924,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LGH447 restored Alpelisib (BYL719) sensitivity in breast cancer cells harboring PIK3CA H1047R and over expressing Pim1 in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 2419,
                "therapyName": "Alpelisib + LGH447",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8914,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Ipatasertib (GDC-0068) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 747,
                "therapyName": "Ipatasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8880,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8925,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 restored Alpelisib (BYL719) sensitivity in breast cancer cells harboring PIK3CA H1047R and over expressing Pim1 in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26492,
                "profileName": "PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 4851,
                "therapyName": "Alpelisib + AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8895,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26493,
                "profileName": "PIK3CA E545K PIM1 over exp"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8901,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA K111N resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26529,
                "profileName": "PIK3CA K111N PIM1 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8900,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R and PTEN E307K resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26530,
                "profileName": "PIK3CA H1047R PIM1 over exp PTEN E307K"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8912,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to BX-795 in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26531,
                "profileName": "PIK3CA H1047L PIM1 over exp"
            },
            "therapy": {
                "id": 3467,
                "therapyName": "BX-795",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8902,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA H1047L resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26531,
                "profileName": "PIK3CA H1047L PIM1 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8903,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cells harboring PIK3CA E545K and L866F resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26533,
                "profileName": "PIK3CA E545K PIK3CA L866F PIM1 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8926,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LGH447 sensitized breast cancer cell lines harboring PIK3CA mutations with elevated Pim1 protein levels to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26534,
                "profileName": "PIK3CA mut PIM1 over exp"
            },
            "therapy": {
                "id": 2419,
                "therapyName": "Alpelisib + LGH447",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8906,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pim1 over expression in breast cancer cell lines harboring PIK3CA mutations resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26534,
                "profileName": "PIK3CA mut PIM1 over exp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8929,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LGH447 sensitized breast cancer cells harboring PIK3CA C420R and with elevated Pim1 protein levels to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26538,
                "profileName": "PIK3CA C420R PIM1 over exp"
            },
            "therapy": {
                "id": 2419,
                "therapyName": "Alpelisib + LGH447",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8928,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LGH447 sensitized breast cancer cells harboring PIK3CA H1047R, PIK3CA P539R, and with elevated Pim1 protein levels to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26539,
                "profileName": "PIK3CA P539R PIK3CA H1047R PIM1 over exp"
            },
            "therapy": {
                "id": 2419,
                "therapyName": "Alpelisib + LGH447",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8927,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LGH447 sensitized breast cancer cells harboring PIK3CA E542K, PTEN E288fs, PTEN T321fs, and with elevated Pim1 protein levels to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26540,
                "profileName": "PIK3CA E542K PIM1 over exp PTEN E288fs PTEN T321fs"
            },
            "therapy": {
                "id": 2419,
                "therapyName": "Alpelisib + LGH447",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 14615,
            "profileName": "PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14616,
            "profileName": "MYC over exp PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18597,
            "profileName": "JAK2 V617F PIM1 over exp PIM2 over exp PIM3 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18598,
            "profileName": "JAK2 V617F PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18599,
            "profileName": "MPL W515L PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19449,
            "profileName": "FLT3 exon 14 ins PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24804,
            "profileName": "PIM1 over exp PIM2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26492,
            "profileName": "PIK3CA H1047R PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26493,
            "profileName": "PIK3CA E545K PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26529,
            "profileName": "PIK3CA K111N PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26530,
            "profileName": "PIK3CA H1047R PIM1 over exp PTEN E307K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26531,
            "profileName": "PIK3CA H1047L PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26533,
            "profileName": "PIK3CA E545K PIK3CA L866F PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26534,
            "profileName": "PIK3CA mut PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26538,
            "profileName": "PIK3CA C420R PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26539,
            "profileName": "PIK3CA P539R PIK3CA H1047R PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26540,
            "profileName": "PIK3CA E542K PIM1 over exp PTEN E288fs PTEN T321fs",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}